Nanjing Carephar Pharmaceutical Co., Ltd.

1. To investigate the safety and tolerability of a single oral dose of H029 tablets in healthy adult participants; 2. To observe the pharmacokinetic (PK) characteristics of a single oral dose of H029 tablets in healthy adult participants, providing a basis for dose selection in future clinical studies; 3. To explore the effects of diet on the PK and safety of H029, studying the effects of diet (high-fat meal) on the safety, tolerability, and PK of oral H029 tablets in healthy adult participants.

Primary purpose: For patients with upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer and high risk of rebleeding, the drug is given after endoscopic treatment to evaluate the effectiveness of H009 injection in reducing the risk of rebleeding, which is non-inferior to esomeprazole sodium for injection (ESO); Secondary purpose: 1) Compared with ESO for injection, H009 injection is given after endoscopic treatment to patients with upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer and high risk of rebleeding to evaluate the effect on rebleeding-related events; 2) Compared with ESO for injection, observe the safety of H009 injection for upper gastrointestinal bleeding caused by acute gastric and/or duodenal ulcer.

Primary objective: To evaluate the effectiveness of H009 injection with different dosage regimens in reducing the risk of rebleeding in patients with acute gastric and/or duodenal ulcer upper gastrointestinal bleeding and high risk of rebleeding after endoscopic treatment compared with Esomeprazole sodium for injection (ESO); Secondary objective: To evaluate the effect of H009 injection with different dosage regimens in reducing the risk of rebleeding in patients with acute gastric and/or duodenal ulcer upper gastrointestinal bleeding and high risk of rebleeding after endoscopic treatment compared with ESO for injection; To observe the safety of H009 injection with different dosage regimens in patients with acute gastric and/or duodenal ulcer upper gastrointestinal bleeding compared with ESO for injection; To observe the population pharmacokinetic characteristics of H009 injection in patients with peptic ulcer bleeding.